XOMA Royalty (XOMA) Net Income towards Common Stockholders (2011 - 2026)
XOMA Royalty (XOMA) reported Net Income towards Common Stockholders of $4.5 million for Q1 2026, up 88.64% on a YoY basis from $2.4 million in Q1 2025, and down 51.13% sequentially from $9.1 million in Q4 2025.
XOMA Royalty (XOMA) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 16 years of Net Income towards Common Stockholders data on file, last reported at $4.5 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 88.64% year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.5 million (up 104.84% YoY), and the FY2025 full-year result was $31.7 million, up 330.58% from the prior year.
- Net Income towards Common Stockholders slipped to $4.5 million in Q1 2026, from $9.1 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $9.1 million in Q4 2025 to a low of -$27.1 million in Q2 2024.
- A 5-year average of -$10.3 million and a median of -$11.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders tumbled 830.49% in 2022 and surged 195.6% in 2025, its largest moves.
- Tracing XOMA's Net Income towards Common Stockholders over 5 years: stood at -$6.3 million in 2022, then tumbled by 225.0% to -$20.3 million in 2023, then jumped by 53.03% to -$9.6 million in 2024, then surged by 195.6% to $9.1 million in 2025, then plunged by 51.13% to $4.5 million in 2026.
- Business Quant data shows XOMA's Net Income towards Common Stockholders at $4.5 million in Q1 2026, $9.1 million in Q4 2025, and -$11.1 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 4.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.47 Mn |
| Dec 31, 2025 | 9.14 Mn |
| Jun 30, 2025 | -11.11 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Dec 31, 2024 | -9.56 Mn |
| Sep 30, 2024 | -17.24 Mn |
| Jun 30, 2024 | -27.06 Mn |
| Mar 31, 2024 | -10.78 Mn |
| Dec 31, 2023 | -20.35 Mn |
| Sep 30, 2023 | -12.59 Mn |
| Jun 30, 2023 | -17.39 Mn |
| Mar 31, 2023 | -11.07 Mn |
| Dec 31, 2022 | -6.26 Mn |
| Sep 30, 2022 | -14.66 Mn |
| Jun 30, 2022 | -20.82 Mn |
| Mar 31, 2022 | -2.12 Mn |
| Dec 31, 2021 | 29.86 Mn |
| Sep 30, 2021 | -4.44 Mn |
| Jun 30, 2021 | -2.24 Mn |
| Mar 31, 2021 | -7.37 Mn |